# US 2019/0167790 A1 · Abt-165 in combination with folinic acid, 5-fluorouracil, and irinotecan for the treatment of cancers > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2019/0167790 A1 - Document ID: US20190167790A1 - Status: Published application - Kind: A1 - Application number: 16/207,758 - Filed: 2018-12-03 - Published: 2019-06-06 - Earliest claimed: 2017-12-05 - Assignees: AbbVie Biotherapeutics Inc. - Applicants: AbbVie Biotherapeutics Inc. - Inventors: Louie Naumovski - Web page: https://patentgrep.com/patent/US20190167790A1 ## CPC - A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines} - A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48) - A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine - A61K 31/519: ortho- or peri-condensed with heterocyclic rings - A61P 35/00: Antineoplastic agents - C07K 16/22: against growth factors {; against growth regulators} - C07K 16/28: against receptors, cell surface antigens or cell surface determinants - A61K 2039/505: {comprising antibodies} - C07K 2317/32: specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor - C07K 2317/35: Valency - C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) ## Abstract This invention pertains to a method for the treatment of cancer in a subject comprising administering to the subject an effective amount of ABT-165 in combination with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI). ## Claims ### Claim 1 A method for the treatment of colorectal cancer in a subject who is in need thereof, comprising administering to the subject an effective amount of a dual-variable domain immunoglobulin molecule with dual specificity for both delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF), ABT-165, dosed at about 2.5 mg/kg in combination with folinic acid and 5-fluorouracil. ### Claim 2 (depends on 1) The method of claim 1, wherein ABT-165 is dosed once every 2 weeks in a subject. ### Claim 3 (depends on 1) The method of claim 1, wherein ABT-165 is dosed in combination with folinic acid, 5-fluorouracil, and irinotecan to a subject. ### Claim 4 (depends on 1) The method of claim 1, wherein ABT-165 is dosed at about 2.5 mg/kg every 2 weeks in combination with folinic acid, 5-fluorouracil, and irinotecan to a subject. ### Claim 5 (depends on 1) The method of claim 1, wherein ABT-165 is dosed at about 2.5 mg/kg every 2 weeks in combination with folinic acid, 5-fluorouracil, and irinotecan to a subject as first line therapy. ### Claim 6 (depends on 1) The method of claim 1, wherein ABT-165 is dosed at about 2.5 mg/kg every 2 weeks in combination with folinic acid, 5-fluorouracil, and irinotecan to a subject as second line or higher therapy. ### Claim 7 A method for the treatment of cancer that is sensitive to FOLFIRI therapy, comprising administering to the subject an effective amount of a dual-variable domain immunoglobulin molecule with dual specificity for both delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF), ABT-165, dosed at about 2.5 mg/kg in combination with folinic acid and 5-fluorouracil, wherein said cancer is selected from the group consisting of: gastroesophageal cancer, pancreatic cancer, breast cancer, glioblastoma multiforme, ovarian cancer, or non-small cell lung cancer in a subject who is in need thereof. ### Claim 8 (depends on 7) The method of claim 7, wherein ABT-165 is dosed once every 2 weeks in a subject. ### Claim 9 (depends on 7) The method of claim 7, wherein ABT-165 is dosed in combination with folinic acid, 5-fluorouracil, and irinotecan to a subject. ### Claim 10 (depends on 7) The method of claim 7, wherein ABT-165 is dosed at about 2.5 mg/kg every 2 weeks in combination with folinic acid, 5-fluorouracil, and irinotecan to a subject. ### Claim 11 (depends on 7) The method of claim 7, wherein ABT-165 is dosed at about 2.5 mg/kg every 2 weeks in combination with folinic acid, 5-fluorouracil, and irinotecan to a subject as first line therapy. ### Claim 12 (depends on 7) The method of claim 7, wherein ABT-165 is dosed at about 2.5 mg/kg every 2 weeks in combination with folinic acid, 5-fluorouracil, and irinotecan to a subject as second line or higher therapy.